Bi-daily tegafur-uracil (UFT) plus leucovorin (LV) versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer, unfit or unwilling to receive combination chemotherapy. - A randomized, open-label phase III study.

Trial Profile

Bi-daily tegafur-uracil (UFT) plus leucovorin (LV) versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer, unfit or unwilling to receive combination chemotherapy. - A randomized, open-label phase III study.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2013

At a glance

  • Drugs Folinic acid (Primary) ; Tegafur/uracil (Primary) ; Capecitabine
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms TLC
  • Most Recent Events

    • 08 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by Netherlands Trial Register.
    • 22 Sep 2009 Additional trial acronym TLC identified as reported by Netherlands Trial Register record.
    • 12 May 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top